Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

GONAL-F RFF REDI-JECT

FOLLITROPIN ALFA/BETA

Standard Dose
300 IU/0.5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview GONAL-F RFF REDI-JECT is listed in Drugs@FDA under application 021684 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient FOLLITROPIN ALFA/BETA Form and strength INJECTABLE;SUBCUTANEOUS - 300 IU/0.5ML Sponsor EMD SERONO Submission history Latest submission status date: 2024-05-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview GONAL-F RFF REDI-JECT is listed in Drugs@FDA under application 021684 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient FOLLITROPIN ALFA/BETA Form and strength INJECTABLE;SUBCUTANEOUS - 300 IU/0.5ML Sponsor EMD SERONO Submission history Latest submission status date: 2024-05-13 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
GONAL-F RFF REDI-JECT (FOLLITROPIN ALFA/BETA) | Drug Monograph | MedicHelpline